ESMO 2025 Highlights

Berlin, October 17–21, 2025

Get the OncoAlert Newsletter

Your role

Your country

How we use your details

Every week, and every day during the major congresses. Free.

News

The faculty’s updates from ESMO 2025, newest first.

HARMONi-6, explained in Japanese
Lung and thoracic. Dr. Hidehito Horinouchi. Expert pick.
Oncología: ahora y en directo
Dra. Regina Barragán-Carrillo. In Spanish.
monarchE: the overall survival update
Breast. Dr. Del Mastro. Expert pick. In Italian.
ASCENT-03 and TROPION-Breast02 in advanced TNBC
Breast. Dr. Del Mastro. Expert pick. In Italian.
Prostate cancer: EMBARK, CAPItello-281, PETRANHA
Genitourinary. Dr. Gil Morgan. Expert pick.
GI oncology: NICHE-2 and STELLAR-303
Gastrointestinal. Dr. Nicholas Hornstein. Expert pick.
Radioligand therapy in prostate cancer
Genitourinary. Dr. Silke Gillessen. Interview.
Kidney cancer: RAMPART, O3A and OPTIC
Genitourinary. Dr. Brian Rini. Expert pick.
Lung cancer: the picks from Berlin
Lung and thoracic. Dr. Biagio Ricciuti. Expert pick.
OPTIC RCC: a biomarker-selected combination
Genitourinary. Dr. Brian Rini. Expert pick.
Breast cancer: the picks from Berlin
Breast. Dr. Elisa Agostinetto. Expert pick.
DISCUS (LBA 109): three or six cycles before avelumab
Genitourinary. Dr. Enrique Grande. Expert pick.
HARMONi-6: ivonescimab in squamous NSCLC
Lung and thoracic. Dr. Hidehito Horinouchi. Expert pick.
IMvigor011: ctDNA after cystectomy
Genitourinary. Dr. Tom Powles. Expert pick.

Round-ups

Dr. Gil Morgan’s round-up of each day, posted the next morning.

IMvigor011
DYNAMIC-III
FORTITUDE-101

Dr. Gil MorganThe OncoAlert Network

Day 4 round-up: IMvigor011, DYNAMIC-III, FORTITUDE-101

ctDNA-guided and biomarker-driven strategies are changing adjuvant and targeted therapy in bladder, colorectal and gastric cancer.

Earlier days

Day 3 round-up: the top five trials
Lung and thoracic. Dr. Gil Morgan. Daily round-up.
Day 2 round-up: five practice-changing trials
Breast. Dr. Gil Morgan. Daily round-up.

The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.

Email address